Climb Bio develops antibody medicines for immune system diseases, including rare kidney and blood disorders. CLYM reports earnings on Wed, Nov 11, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (8 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 20 | Deutsche Bank | Initiated | Buy | |
| Sep 8 | Oppenheimer | Maintained | Buy | |
| Sep 8 | HC Wainwright & Co. | Target raised | Buy | |
| Sep 4 | B. Riley Securities | Reiterated | Buy | |
| Sep 3 | BTIG | Target raised | Buy |
Whale Options Flow
90DNo whale options trades in CLYM in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CLYM is in one of them and how their past CLYM trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CLYM in an article yet. Here's the latest on the wider market.
About Climb Bio
Climb Bio is a biotechnology company based in Wellesley Hills, Massachusetts. It is developing antibody medicines for diseases in which the immune system attacks the body. Its lead candidate, budoprutug, is designed to deplete a type of B cell and is being tested in patients with membranous nephropathy, a rare kidney disease, as well as immune thrombocytopenia and lupus. A second candidate, CLYM116, targets a protein linked to IgA nephropathy, a kidney condition. Its candidates are still in clinical trials and are not yet sold.
- Headquarters
- Wellesley Hills, MA